MELBOURNE, Australia, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) announces that its American Depository Shares (ADSs) have commenced trading on the Nasdaq Global Select Market (Nasdaq) under the ticker symbol ‘TLX’. The Company continues to have its primary listing on ASX, with the Nasdaq listing of ADSs expected to complement the Company’s ASX listing. Each ADS represents...Read more
BOSTON, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced the pricing of its initial public offering of 17,500,000 shares of its common stock at a public offering price of $18.00 per share. Bicara Therapeutics’ shares are expected to begin trading on the Nasdaq...Read more
CARMEL, Ind., Sept. 12, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX) (“MBX Biosciences”), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the pricing of its initial public offering of 10,200,000 shares of its common stock at a price to the public of $16.00 per share. The gross...Read more
CARMEL, Ind., September 9, 2024 (GLOBE NEWSWIRE) – MBX Biosciences, Inc. (“MBX Biosciences”), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the launch of its initial public offering of 8,500,000 shares of its common stock pursuant to a registration statement filed with the Securities and...Read more
Hangzhou, China, Aug. 26, 2024 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (Nasdaq: WOK) (the "Company"), a supplier of medical devices in China, today announced the closing of the initial public offering (the "Offering") of its 2,000,000 ordinary shares at a public offering price of US$4.00 per ordinary share. The ordinary shares commenced trading on the Nasdaq Capital Market on August 23, 2024 under the ticker symbol...Read more
NEW YORK, Aug. 23, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (“Eyenovia” or the “Company”) (NASDAQ: EYEN), a commercial-stage ophthalmic company, announced today the closing of its public offering of 12,850,000 shares of common stock at a price per share of $0.40 (the "Offering"). The gross proceeds to Eyenovia from this Offering are approximately $5.14 million, before deducting the placement agent’s fees and other offering expenses...Read more
CHICAGO and FORT WORTH, Texas, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (Nasdaq: ACTU) (the “Company”), a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers, announced today the pricing of its initial public offering of 2,800,000 shares of its common stock, at a price of $8.00 per share to the public for a total of $22,400,000 of gross...Read more
ROCKVILLE, Md. & NEW YORK / Jul 31, 2024 / Business Wire / OS Therapies Incorporated (“OS Therapies” or the “Company”) (NYSE-A: OSTX), an Antibody Drug Conjugate (ADC) and Immunotherapy research and clinical stage biopharmaceutical company, today announced the pricing of its initial public offering of 1,600,000 shares of common stock at a public offering price of $4.00 per share, raising gross proceeds of $6.4 million. Additionally, the...Read more
BRENTWOOD, Tenn. / Jul 19, 2024 / Business Wire / Ardent Health Partners, Inc. (NYSE: ARDT) (f/k/a Ardent Health Partners, LLC and collectively “Ardent Health” or the “Company”), a leading provider of healthcare in growing midsize urban communities across the U.S., today announced the closing of its initial public offering (the “Offering”) of 12,000,000 shares of its common stock sold by the Company at a public offering price of $16 per...Read more
Regular Way Trading on Nasdaq Global Select Market to Begin Tomorrow, June 25 GRAIL is Building and Scaling a Groundbreaking New Cancer Screening Technology MENLO PARK, Calif., June 24, 2024 — GRAIL, Inc. (NASDAQ: GRAL, formerly GRAIL, LLC), a healthcare company whose mission is to detect cancer early when it can be cured, today announced its spin-off from Illumina (NASDAQ: ILMN) is complete, and GRAIL will be listed and...Read more
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE